Rectal Cancer - Pipeline Review, H1 2013


#164386

88pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Rectal Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rectal Cancer. 

Rectal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • A snapshot of the global therapeutic scenario for Rectal Cancer.
  • A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Rectal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Rectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Rectal Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Rectal Cancer 9
Rectal Cancer Therapeutics under Development by Companies 11
Rectal Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Rectal Cancer Therapeutics - Products under Development by Companies 19
Rectal Cancer Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Rectal Cancer Therapeutics Development 22
Sanofi-Aventis 22
Eli Lilly and Company 23
GenVec, Inc. 24
Merck & Co., Inc. 25
Merck KGaA 26
Peregrine Pharmaceuticals, Inc. 27
Synta Pharmaceuticals Corp. 28
Nanobiotix 29
Isofol Medical AB 30
Rectal Cancer - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
emepepimut-S - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TNFerade - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ganetespib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
bavituximab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
nelfinavir mesylate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
erlotinib hydrochloride + [bevacizumab] + [fluorouracil] + Radiation Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
aspirin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
bevacizumab + [cetuximab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
cixutumumab + [cetuximab] + [irinotecan hydrochloride hydrochloride] - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
XELOX + Radiotherapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dalotuzumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
modified vaccinia virus ankara vaccine expressing p53 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
selumetinib sulfate + [capecitabine] + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TS-1 + Oxaliplatin + Cetuximab + Radiation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TS-1 + Oxaliplatin + Cetuximab + Radiation - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tegafur + gimeracil + oteracil potassium - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Modufolin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Modufolin + [pemetrexed disodium] - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
midostaurin + [fluorouracil] - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
linifanib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
panitumumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Rectal Cancer Therapeutics - Drug Profile Updates 75
Rectal Cancer Therapeutics - Dormant Products 83
Rectal Cancer - Product Development Milestones 84
Featured News & Press Releases 84
Nov 03, 2012: Merck KGaA Ceases Supply Of Cancer Drug Erbitux To Greek Hospitals 84
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 84
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 85
Apr 15, 2011: Isofol Medical Enrolls First Patient In Initial Trial With Modufolin For Treatment Of Neoadjuvant Rectal Cancer 86

Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

Number of Products Under Development for Rectal Cancer, H1 2013 9
Products under Development for Rectal Cancer - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 21
Sanofi-Aventis, H1 2013 22
Eli Lilly and Company, H1 2013 23
GenVec, Inc., H1 2013 24
Merck & Co., Inc., H1 2013 25
Merck KGaA, H1 2013 26
Peregrine Pharmaceuticals, Inc., H1 2013 27
Synta Pharmaceuticals Corp., H1 2013 28
Nanobiotix, H1 2013 29
Isofol Medical AB, H1 2013 30
Assessment by Monotherapy Products, H1 2013 31
Assessment by Combination Products, H1 2013 32
Assessment by Stage and Route of Administration, H1 2013 34
Assessment by Stage and Molecule Type, H1 2013 36
Rectal Cancer Therapeutics - Drug Profile Updates 75
Rectal Cancer Therapeutics - Dormant Products 83
Number of Products under Development for Rectal Cancer, H1 2013 9
Products under Development for Rectal Cancer - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 31
Assessment by Combination Products, H1 2013 32
Assessment by Route of Administration, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 34
Assessment by Molecule Type, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 36